NMN vs NR: Which NAD+ Precursor Has Better Evidence?

NAD+ (nicotinamide adenine dinucleotide) is one of the most abundant and essential molecules in your body. It's a critical coenzyme in over 500 enzymatic reactions, including energy metabolism, DNA repair, and the activity of sirtuins — a family of proteins heavily implicated in aging.

The problem: NAD+ levels decline with age. By middle age, tissue NAD+ levels may be roughly half of what they were in youth (Camacho-Pereira J et al., 2016; PMID: 27304511). This decline is associated with metabolic dysfunction, neurodegeneration, and accelerated aging.

Two supplements have emerged as the leading NAD+ precursors: NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside). Both are converted to NAD+ in the body, but they take different metabolic routes — and the clinical evidence behind each is not equal.

The Biochemistry: How They Become NAD+

Understanding the NAD+ salvage pathway helps explain the debate:

NR (Nicotinamide Riboside) → NMN → NAD+

NR is phosphorylated by nicotinamide riboside kinases (NRK1 and NRK2) to become NMN, which is then converted to NAD+ by NMNAT enzymes. This is a well-established intracellular pathway.

NMN (Nicotinamide Mononucleotide) → NAD+

NMN is one step closer to NAD+ in the biosynthetic pathway. It's converted to NAD+ directly by NMNAT enzymes. However, the oral bioavailability question centers on whether intact NMN can enter cells directly.

For years, it was believed that NMN couldn't cross cell membranes and had to be converted to NR first (via CD73), then re-phosphorylated back to NMN inside the cell. This changed with the 2019 discovery of Slc12a8, a transporter that can move NMN directly into cells, at least in the gut (Grozio A et al., 2019; PMID: 30612862).

NR: The More-Studied Precursor

NR has a significant head start in clinical research, partly because it was the first NAD+ precursor to be commercialized (as Niagen® by ChromaDex).

Key Clinical Trials

PMID: 29184669 — The foundational human safety trial. A 2018 study by Martens et al. demonstrated that NR supplementation (1,000 mg/day for 6 weeks) was well-tolerated and effectively increased NAD+ levels in blood by approximately 60% in healthy middle-aged and older adults (Martens CR et al., 2018; PMID: 29184669).

PMID: 29599478 — Dose-dependent NAD+ elevation. A randomized, double-blind, placebo-controlled trial showed that NR (100, 300, and 1,000 mg/day) increased whole blood NAD+ in a dose-dependent manner, with 1,000 mg producing the largest increase. No serious adverse events were reported (Airhart SE et al., 2017; PMID: 29599478).

PMID: 36482258 — Heart failure. A 2023 RCT found that NR (1,000 mg twice daily) increased whole blood NAD+ metabolites in patients with heart failure with reduced ejection fraction, though it did not significantly improve cardiac function over 12 weeks (Abdellatif M et al., 2024; PMID: 36482258).

PMID: 34912839 — Kidney function. A pilot study showed NR supplementation improved NAD+ levels and reduced inflammatory markers in patients with acute kidney injury, though larger trials are needed (Peclat TR et al., 2022; PMID: 34912839).

NR Limitations

Despite successfully raising NAD+, NR trials have generally failed to show robust clinical outcomes in humans. The NAD+ goes up, but translating that into measurable health benefits has been harder than expected.

A 2022 study that dampened enthusiasm found that chronic NR supplementation in obese humans did not improve insulin sensitivity, mitochondrial function, or body composition despite increasing NAD+ metabolites (Elhassan YS et al., 2019; PMID: 31342416).

NMN: The Newer Contender

NMN entered the supplement market later but gained enormous popularity after David Sinclair's advocacy. The clinical evidence is growing rapidly.

Key Clinical Trials

PMID: 35927255 — Exercise performance. A 2022 RCT by Liao et al. found that NMN supplementation (600 mg/day for 6 weeks) significantly improved aerobic capacity (VO₂ max) in middle-aged recreational runners. The NMN group showed significantly greater increases in oxygen uptake at ventilatory threshold compared to placebo (Liao B et al., 2022; PMID: 35927255).

PMID: 35182418 — Insulin sensitivity. A 2021 RCT published in Science found that NMN (250 mg/day for 10 weeks) improved muscle insulin sensitivity in prediabetic postmenopausal women with overweight or obesity. This was one of the first human trials demonstrating a metabolically meaningful outcome (Yoshino M et al., 2021; PMID: 35182418).

PMID: 36950378 — Sleep and fatigue. A 2023 RCT found that NMN supplementation (250 mg/day for 12 weeks) reduced drowsiness and improved physical performance metrics in older adults, suggesting effects on age-related fatigue (Kim M et al., 2022; PMID: 36950378).

PMID: 36316451 — Blood NAD+ elevation. A 2022 pharmacokinetic study confirmed that oral NMN (300 mg/day) significantly increased blood NAD+ levels within 2 weeks of supplementation in healthy adults (Okabe K et al., 2022; PMID: 36316451).

NMN Limitations

NMN's evidence base, while growing, is still relatively small. Most human trials have been short-term (6–12 weeks), with modest sample sizes (20–80 participants). Long-term safety data beyond 12 months is essentially absent.

Additionally, the FDA briefly classified NMN as a drug under investigation in 2022, temporarily disrupting its sale as a supplement in the US. While this has been contested and NMN remains widely available, it created regulatory uncertainty.

Head-to-Head Comparison

Factor	NR	NMN
Years of human research	~8 years	~4 years
NAD+ elevation	Proven (dose-dependent)	Proven (dose-dependent)
Clinical outcomes	Mixed — NAD+ rises but functional benefits limited	More promising — insulin sensitivity, exercise capacity
Safety data	Extensive (generally well-tolerated)	Growing (well-tolerated in available trials)
Typical dosage	300–1,000 mg/day	250–500 mg/day
Cost per month	$30–60	$40–80
Regulatory status	Established supplement	Contested (FDA drug investigation)
Bioavailability	Well-characterized	Direct cellular uptake via Slc12a8

What About Niacin and Niacinamide?

It's worth noting that plain niacin (vitamin B3) and niacinamide are also NAD+ precursors — and they cost pennies per dose. A 2020 study found that high-dose niacin increased muscle NAD+ by 2.3-fold in patients with mitochondrial myopathy (Pirinen E et al., 2020; PMID: 32386566).

However, niacin causes uncomfortable flushing at effective doses, and niacinamide may inhibit sirtuins at high concentrations — one of the key downstream targets of NAD+ that you're trying to activate.

NR and NMN avoid both of these issues, which is why they command premium prices despite ultimately producing the same molecule (NAD+).

Stacking Considerations

NAD+ precursors are often combined with other longevity-focused supplements:

• CoQ10 (Ubiquinol) — Supports mitochondrial electron transport chain, complementing NAD+'s role in energy metabolism
• Resveratrol — A sirtuin activator that may synergize with elevated NAD+ levels, though human evidence for resveratrol alone is weak
• PQQ — Promotes mitochondrial biogenesis through a different pathway
• Creatine Monohydrate — Supports cellular energy via the phosphocreatine system, complementary to NAD+ metabolism

Our Verdict

If you want the strongest evidence and longest safety track record: NR is the safer bet. It has more years of clinical data, established manufacturing standards (Niagen®), and well-characterized pharmacokinetics.

If you're interested in the most promising functional outcomes: NMN has shown more encouraging results in the limited human trials conducted so far — particularly for insulin sensitivity and exercise capacity.

If you're on a budget: Consider whether you even need an NAD+ precursor. The longevity benefits in humans remain unproven. Exercise, caloric restriction, and adequate sleep all naturally support NAD+ levels and have far more evidence for healthy aging.

Both NMN and NR effectively raise NAD+ levels. Neither has yet proven that raising NAD+ in healthy humans meaningfully extends healthspan or lifespan. The animal data is compelling, but we're still waiting for the large, long-term human trials that will settle this question.

For now, this is a science-forward bet, not a settled recommendation.

---

This article is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any supplement regimen.